H. Loetscher, manuscript submitted for publication) . The htr-5 and htr-9 are both of IgGl isotype and htr-1 is an IgM antibody. These antibodies were affinity purified from hybridoma supernatants by using rabbit anti-mouse Ig linked to Sepharose 4B (Pharmacia Fine Chemicals, Uppsala, Sweden) . rTNFa and affinity-purified htr-5 and htr-9 were for some experiments labeled with biotin as previously described (16) . The pfa-11, an IgG, mouse mAb that recognizes human platelet-derived growth factor A chain, was used as a control . Streptavidinphycoerythrin was purchased from Becton Dickinson & Co., Mountain View, CA.
Flow Cytometric Quantification of TNF Receptor Antibody Binding and rTNF-a Binding. U937 and HL-60 cells (American Type Culture Collection, [ATCC] , Rockville, MD) were grown in RPMI 1640 (Gibco Laboratories, Paisley, Scotland) supplemented with 10% heat-inactivated FCS (Gibco), 2 MM r.-glutamine, and 40 Fig/ml gentamicin (complete RPMI 1640). Binding ofTNF receptor antibodies or rTNFci to cells was done by adding 10 tog/ml of biotinylated antibodies or 50 ng/ml of biotinylated rTNFa (BrTNFa) diluted in PBS with 0.1% BSA (Sigma Chemical Co., St. Louis, MO) to 106 cells for 45 min at 0-4°C. The cells were then washed twice in PBS/BSA and were stained with 20 1A of streptavidin-phycoerythrin for 45 min at 0-4°C. The cells were subsequently washed once in PBS and fixed in 2% formalin (Merck, Darmstadt, Federal Republic ofGermany) and stored at 0-4°C until they were analyzed using a FACScan flow cytometer (Becton Dickinson & Co.). Blocking experiments were done by pretreating cells with one of the following reagents: 50 Ftg/ml of rTNFa, 50 Ftg/ml ofrTNF0, 10,ug/ml ofhtr-9 or htr-5 for 45 min at 0-4 0C before addition of the biotinylated reagent. For flow cytometric analysis 5 x 10' cells were acquired by list mode and measurements were performed on a single cell basis and were displayed as frequency distribution histograms.
Cytotoxicity Assay. About 3 x 106 U937 cells were labeled with 300 uCi Na?'Cr04 (Amersham, Buckinghamshire, UK) for 90 min at 37°C, followed by two washes in RPMI 1640 and one wash in complete RPMI 1640. 100 Al of labeled U937 cells (10 5 cells/ml) in complete medium were added to flat-bottomed microtiter plates (Costar, Cambridge, MA) together with 100 ul of different dilutions of TNF receptor antibodies or rTNFa . After 20 h ofincubation at 37°C, 100,u] of supernatants were harvested and their radioactivity was measured in an LKB Wallac 1270 gamma counter (Turku, Finland). Percent specific lysis was calculated as follows : percent specific lysis = 100 x [(A-B)/(C-B)]. where A represents cpm from test supernatants ; B represents cpm from supernatants with target cells alone (spontaneous release) ; and C represents cpm after lysis of target cells with 0.25 0/0 SDS (maximum release) . Results are presented as the mean ± SE of triplicate cultures . Spontaneous release from U937 cells alone was <25% for all experiments .
Thymidine Incorporation Assay. Fs4 fibroblasts (generously provided by Dr. J. VWek, New York University, New York, NY) were grown in complete RPMI 1640. 100 Al of 105 cells/ml were dispensed in triplicate wells in flat-bottomed microtiter plates (Costar) together with 100 p.l ofdifferent dilutions ofTNF receptor antibodies or rTNFci . After 72 h of incubation 1 ttCi methyl-['H]thymidine (Amersham) was added to each well 4 h before harvesting the cultures with a Titertek cell harvester (Flow Laboratories, Ayrshire, UK). Radioactivity was measured by liquid scintillation counting in an LKB Wallac 1215 beta counter. Results are presented as cpm t SE of triplicate cultures.
Human Endothelial Cell Cultures andAssays. Human endothelial cells (HEC) were obtained by collagenase (Sigma Chemical Co.) treatment of human umbilical cord veins as described (17) . The identity ofHEC was confirmed as detailed in a previous report (18) . The cells were seeded at uniform density (0.15 x 106/well) in 24-well plates (Costar) using complete RPMI 1640. For the induction of IL-6, cultures ofconfluent HEC monolayers were incubated with or without the addition of different concentrations of TNF receptor antibodies or rTNFa. After 24 h ofincubation the supernatants were collected and tested for IL-6 activity as detailed previously (18) . For adhesion of HL-60 cells, cultures of confluent HEC monolayers were subjected to treatment with TNF receptor antibodies or rTNFa for 5-6 h at 37°C. HEC monolayers were then washed twice with HBSS (Gibco) and each culture received 250 J1 of complete RPMI 1640 containing 0.5 x 105 "Cr HL-60 (HL-60 were labeled with "Cr and washed as described above). After 1 h of incubation nonadherent "Cr HL-60 cells were removed and after four washes with HBSS HEC cultures received 250 Al of 1% Triton-100 (Sigma Chemical Co.) and were further incubated for 1 h to lyse the cells . The radioactivity was determined by counting aliquots ofcell lysate using LKB Wallac 1270 gamma counter. Maximum count was obtained from 0.1% Triton-100-treated 0.5 x 105 "Cr HL-60 cells . The mean cpm as a reflection of "Cr HL-60 adherence is expressed as percentage of the mean maximum cpm .
Results
Specificity of Binding of TNF Receptor Antibodies to U937 Cells. Experiments were carried out to quantify the binding of htr-9 and htr-5 to U937 cells and to see if rTNFa or rTNF(3 could inhibit the binding ofthese TNF receptor antibodies. The results are shown in Fig . 1 and demonstrate that biotinylated (B) htr-9 significantly bound to U937 cells and that pretreatment ofthe cells with either rTNFa or rTNF# reduced the binding almost to background level (Fig. 1, A and B) . These data indicate that htr-9 recognizes an epitope of a TNF receptor that is common for TNFa and TNFj6 binding . Similar experiments were also performed with htr-5. As shown in reduced Bhtr-5 binding. These results suggest that htr-5 recognizes an epitope of a TNF receptor that is mainly involved in binding of TNF-a but to a lesser extent TNF(3 . The structural differences among the epitopes of the TNF receptor as recognized by htr-9 and htr-5 were further studied in another set of blocking experiments. U937 cells were pretreated with htr-1 or htr-5 antibodies and thereafter stained with Bhtr-9 before they were analyzed by flow cytometry. The results are shown in Fig. 2 , A and B and demonstrate that htr-1 and htr-5 inhibited the binding of Bhtr-9 . These data indicate that htr-9 recognizes an epitope of a TNF receptor that is overlapping with epitopes recognized by htr-5 and htr-1 . A similar experiment was done to examine the binding of Bhtr-5 after pretreatment with htr-1 and htr-9. It was found that htr-9 did not inhibit the binding of Bhtr-5, whereas htr-1 inhibited the Bhtr-5 binding ( Table I .
Ejects of TNF Receptor Antibodies on BrTNF-ct Binding to U937 andHL-60 Cells. As htr-5 was found to inhibit the binding of Bhtr-9, it was of interest to see if this antibody also inhibited BrTNFa binding. U937 and HL-60 cells were pretreated with rTNF a or htr-5 and thereafter stained with BrTNFa and analyzed by flow cytometry. As shown in Fig. 3 A htr-5 only minimally inhibited the binding of BrTNFa to U937 cells. However, htr-5 was far more effective to inhibit the binding of BrTNFa to HL-60 cells (Fig. 3 B) . Similar results were also obtained by using htr-9 pretreatment (data not shown) .
Biological Effects of TNF Receptor Antibodies on U937 Cells. The htr-1, htr-5, and htr-9 antibodies bind to epitopes associated with a TNF receptor (Fig . 1) . Efforts were therefore made to determine whether these antibodies could mimic or block the biological effects of TNFa in different target cell systems. The htr-1, htr-5, and htr-9 antibodies were first tested if they had any cytotoxic activity on U937 cells. The results shown in Fig. 4 demonstrate that htr-1 and htr-9 induced a high degree of cytolysis, whereas htr-5 was ineffective in this respect. When compared in molar terms, -103 to 10 4 times more of htr-9 than rTNFa was needed in order to mediate a comparable level of cytolytic activity. The IgM antibody, htr-1, was -100 times more effective than htr-9 in inducing cytotoxicity of U937 (Fig . 4) . These data suggest that htr-1 and htr-9 recognize an epitope of a TNF receptor that is involved in inducing the cytotoxic activity of TNFa. As the binding studies indicated that htr-5 inhibited htr-9 binding, it was of interest to examine whether htr-5 could also inhibit the cytotoxic activity of htr-9. Cytotoxicity mediated by htr-9 was subsequently determined in the absence and presence of 1014g/ml htr-5 . As expected, htr-5 completely inhibited the cytotoxic activity of htr-9 (Fig. 4 B) . It was also tested if htr-5 was able to inhibit the cytotoxic action of rTNF a. The results in that htr-5 did not completely inhibit the cytotoxicity, but shifted the rTNFa doseresponse curve ti 10-fold. The control antibody pfa-11 did not inhibit htr-9-or TNFa-mediated cytolysis (data not shown) .
Biological Effects of TNFReceptorAntibodies on Fs4 Fibroblasts. The different biological effects of TNFa depend on the target cells used. It was therefore of interest to see if the TNF receptor antibodies also could mimic the growth-stimulating activity ofTNFci on human Fs4 fibroblasts. Both htr-1 and htr-9 induced a dose related increase in thymidine incorporation in Fs4 cells (Fig. 6 A) . In contrast, htr-5 did not have any effect on thymidine incorporation (Fig . 6 A) . Also in this system, htr-1 was the most effective antibody in mimicking TNFa activity (Fig. 6 A) . Approximately 102 times more of htr-9 than rTNFa was needed in order to obtain comparable proliferative activities (data not shown). As was the case with U937, htr-5 was able to completely block the proliferative activity induced by htr-9 on Fs4 cells (Fig. 6 B) . In contrast, rTNF a induced proliferation of Fs4 cells was not affected by htr-5 treatment (data not shown) . These data suggest that the epitope recognized by htr-9 antibody is involved in TNFa signal for stimulating the growth of Fs4 cells.
Biological Effects of TNF Receptor Antibodies on Human Endothelial Cells. The effects of TNF receptor antibodies on IL-6 production by HEC were studied in a direct comparison with the effects ofrTNFa and the results are presented in Table II . Consistent with data reported recently (18) rTNFa caused a substantial stimulation of IL-6 production after 24 h of incubation . While pfa-11 and htr-5 had little effects, antibody h'tr-9 induced a marked increase in IL-6 production reaching 2.45 folds greater than the amounts detected in control HEC cultures (Table II) . The presence of htr-1 also caused a marked enhancement of IL-6 production (not shown) .
One of the important biological properties of TNFci is its ability to increase the adhesiveness of HEC (19) . Therefore, the ability ofhtr-9 antibody to mimic TNFci effect was tested in an adhesion assay using "Cr HL-60 and the results are presented in Table III . HEC treated with htr-9 (0.1-1 14g/ml) showed an increased adhesiveness similar to that observed after treatment with rTNFa as reflected by the adherence of 51
Cr HL-60 cells. Htr-5 did not have any effect on the adhesiveness. However, htr-5 was able to completely block the effect of htr-9 also in this system. Furthermore, htr-5 could partially inhibit rTNFa-induced adhesiveness. The treatment of HEC monolayers with an irrelevant antibody, pfa-11, did not have any effect (data not shown), indicating the specificity of the observed htr-9 effect . The results presented in Tables II and III have been generated against partially purified TNFa binding proteins isolated from HL-60 cells, and all three antibodies recognize noncarbohydrate epitopes on the extracellular domain of a human TNF receptor (Brockhaus, M., and H. Loetscher, manuscript submitted for publication) . The properties of the molecules recognized by these antibodies will be presented elsewhere (Brockhaus, M., and H . Loetscher, manuscript submitted for publication) . These TNF receptor antibodies are species specific as they do not recognize TNF receptors on murine cells like WEHI 164 or L929 (Brockhaus, M., and H . Loetscher, manuscript submitted for publication) . The binding specificity of these antibodies was examined by using biotinylated anti- Cultures of confluent HEC monolayers were incubated in medium only and in medium plus either rTNF-a, htr-9, or htr-5 as indicated . After 4 h, the cultures were washed twice with HBSS and each culture received 105 5'Cr HL-60 in 0.25 ml medium and was further incubated for 1 h. Nonadherent cells were aspirated, the cultures were washed, and adherent 5'Cr HL-60 were lysed for determination of retained radioactivity . Each treatment was performed in duplicate and the data are presented as mean cpm from four lysate aliquots counted . None 4 rTNF-a (10 U/ml) 96 Htr-9 (0 .1 ug/ml) 47 Htr-9 (1 hg/ml) 73 Htr-5 (1 ug/ml) 5 Htr-9 (0 .1 Wg/ml) + htr-5 (1 ug/ml) 6 Htr-9 (1 Rg/ml) + htr-5 (1 ug/ml) 6 rTNF-a (10 U/ml) + htr-5 (1 ug/ml) 69 bodies and flow cytometric quantification . htr-5 and htr-9 both bound to the plasma membrane of U937 cells. Inhibition of the binding by pretreatment with rTNF a demonstrated the specificity ofthese antibodies for the TNF receptor. Furthermore, the binding studies demonstrated that htr-9 recognized an epitope that was shared by htr-5 and htr-1, while htr-5 recognized an epitope that was shared by htr-1 but not by htr-9. The most likely explanation ofthese results is that htr-5 and htr-9 recognize two different but spatially related epitopes on the same TNF receptor molecule . It is unclear whether the epitopes recognized by htr-1 and htr-9 are identical. The result that htr-1, but not htr-9, inhibited htr-5 binding could be due to the fact that htr-1 is an IgM antibody that is larger than htr-9 and thereby can cause steric hindrance for htr-5 binding.
To our surprise we found that TNF0 did not reduce the binding of htr-5 to U937 cells to the same extent as TNFa did. Many of the biological activities of TNFa are shared by TNF0 (3, 4) . However, there are differences between TNF-ci and TNFQ activities in some systems. In human endothelial cells a higher dose of TNF0 is needed compared with TNFa in order to induce similar activities (20) . Aggarwal et al. have found that TNF-ci and TNF0 compete with "5ITNFa for binding to the same receptor (12) . The finding that htr-9 binding was blocked by rTNFoi and rTNF /3 is consistent with the presence of a common receptor for both forms ofTNF. However, the presence ofspecific epitopes for each cytokine is evident from our binding studies with htr-5. These epitopes may determine the affinity of each cytokine for corresponding receptor-cytokine interaction.
We have demonstrated that the htr-1 and htr-9 antibodies,against the TNF receptor mimic the action of rTNFa on U937 cells, Fs4 fibroblasts, and endothelial cells. The htr-5 antibody had no TNF-ci activity in these systems. However, htr-5 completely inhibited the biological activity ofhtr-9 on U937 cellsand on Fs4 fibroblasts. These results further give support to the observation that htr-5 and htr-9 recognize different but overlapping epitopes ofthe TNF receptor. Furthermore, the data strongly indicate that a common epitope of a TNF receptor is involved in inducing cytotoxicity of tumor cells, proliferation of fibroblasts, and activation of endothelial cells for IL-6 production and tumor cell adherence. The biological activities ofhtr-1 and htr-9 were different than the recently described antibody (anti-Fas) that was reported to recognize an antigen associated with a TNF receptor and that killed cells that were not susceptible to the cytolytic action of TNF-ci (21) . Our data suggest that htr-1 and htr-9 detect an epitope of a TNF receptor that is present on TNFsensitive U937 cells, Fs4 fibroblasts and endothelial cells and induce TNFa activity. The results showing TNFlike activity for the antibody htr-9 are in accordance with the observation that the same antibody as well as TNF activate the transcription factor NFKB in the nuclei of HL-60 and HEp2 cells (Hohmann, H., H. Loetscher, M. Brockhaus, R. Remy, and A. P G. M. van Loon, manuscript submitted for publication).
The binding studies with BrTNFa revealed that pretreatment with htr-5 or htr-9 only partially reduced BrTNFci binding to U937 cells, whereas the inhibition of BrTNFa binding by htr-5 or htr-9 pretreatment was much more pronounced in HL-60 cells. In addition, htr-5 only partially inhibited the biological activity ofTNFa on U937 and endothelial cells but not on Fs4 cells. These results could be due to the far lower affinity ofthe antibodies for the TNF receptor compared with the ligand.
It is also possible that TNF receptors other than the one recognized by htr-5 and htr-9 are involved in binding and signaling of TNFa in different cell types . The data also suggest that there are differences between cell types with regard to expression of TNF receptors as HL-60 cells express more of the receptor recognized by htr-5 compared with U937 cells. These results are in accordance with Brockhaus and Loetscher (manuscript submitted for publication) who have identified two types of TNF receptors on human cell lines by using mAbs. The functional relationship between the apparently different TNF receptor types is not clear and requires further studies .
Summary
Three different antibodies against a human TNF receptor (htr-1, htr-5, and htr-9) have been examined for their binding pattern to U937 cells and ability to mimic TNF a activity in U937 cells, Fs4 fibroblasts, and human endothelial cells. Flow cytometric analysis revealed that htr-5 and htr-9 bound specifically to a TNF receptor on U937 cells that could be blocked by pretreatment with rTNFa . Pretreatment of U937 cells with rTNF(3 blocked the binding of htr-9, but to a lesser extent htr-5 binding. Pretreatment with htr-5 inhibited the binding of htr-9 to U937 cells while pretreatment with htr-9 did not inhibit htr-5 binding . These results indicate that htr-5 and htr-9 recognize distinct but overlapping epitopes ofa human TNF receptor on U937 cells and that htr-5 may be close to a TNFa-specific domain ofthe binding site. Pretreatment with htr-5 or htr-9 only minimally reduced binding of BrTNF-a to U937 cells; however, these antibodies were much more effective in inhibiting BrTNF a binding to HL-60 cells . Furthermore, it was found that htr-1 and htr-9, but not htr-5, had TNFci activity on U937 cells, Fs4 fibroblasts, and endothelial cells and that the TNF a activity induced by htr-9 was completely inhibited by htr-5 . However, the cytotoxic activity of TNFci was only partially inhibited by htr-5 on U937 cells while htr-5 had no effect on TNFci activity on Fs4 cells. The data suggest that a common epitope is involved in inducing TNF a activity in three different cell systems .
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